These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 34400269)
1. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269 [TBL] [Abstract][Full Text] [Related]
2. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075 [TBL] [Abstract][Full Text] [Related]
3. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160 [TBL] [Abstract][Full Text] [Related]
4. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial). Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443 [TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664 [TBL] [Abstract][Full Text] [Related]
8. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal. Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820 [TBL] [Abstract][Full Text] [Related]